TVRD

Business Context and Reporting Period

Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company developing oral, small molecule STAT3 inhibitors (TTI-101 and TTI-109) for inflammatory and proliferative diseases. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment and has no product revenue to date. Following a merger with Cara Therapeutics, Inc. in April 2025, the company continues to advance its pipeline while facing significant liquidity challenges.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $2.8 million (29%) compared to Q1 2025. This improvement was primarily driven by the absence of a $5.5 million "Other Expense" in Q1 2026, which in Q1 2025 consisted of a $4.9 million fair value remeasurement loss on Convertible Notes and $0.6 million in accrued interest. These notes converted to equity in April 2025.
• Operating Expense Increase: Total operating expenses increased by $2.7 million (62%). Research and Development (R&D) expenses rose $1.8 million, largely due to a $2.5 million increase in costs for the TTI-109 program (healthy volunteer study and CMC costs). General and Administrative (G&A) expenses increased $0.9 million, driven by higher personnel costs (stock-based compensation) and professional fees related to public company compliance post-merger.
• Cash Flow: Net cash used in operating activities improved by $1.8 million to $5.9 million, reflecting the lower net loss and changes in working capital. Investing activities provided $5.0 million in cash due to maturities of short-term investments, whereas Q1 2025 saw a net use of $10.9 million due to heavy investment purchases.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management has concluded that conditions raise substantial doubt about the company's ability to continue as a going concern. Current capital resources are insufficient to fund operations for at least one year from the filing date. The company plans to seek additional funding through equity offerings, debt, or strategic alliances, but access to capital is not assured.
• Clinical Developments:
  • TTI-101: Preliminary data from the Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF) reported in October 2025 did not meet primary goals. The company is evaluating subset data showing reductions in fibrosis markers. Phase 1b/2 trials in Hepatocellular Carcinoma (HCC) are ongoing.
  • TTI-109: A Phase 1 trial in healthy volunteers was initiated in mid-2025. Topline data is expected in June 2026.
• Capital Raising: On May 1, 2026, the company filed a shelf registration statement (Form S-3) allowing for the sale of up to $200 million in securities, including an At-The-Market (ATM) facility for up to $12.5 million. Sales cannot commence until the registration is declared effective by the SEC.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, including a lack of sufficient finance professionals, inadequate review of financial statements, and insufficient monitoring activities. Remediation efforts are underway.
• Legal Proceedings: A complaint was filed on March 6, 2026, alleging breach of a Registration Rights Agreement regarding the timeliness of a resale registration statement. The company states this is unlikely to have a material adverse effect.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for the effectiveness of the Form S-3 registration statement and the company's ability to execute the ATM facility to bridge the funding gap.
• TTI-101 IPF Data: Monitor upcoming communications regarding the interpretation of the IPF trial data and the decision on future development in this indication.
• Internal Control Remediation: Track progress on remediation of material weaknesses in financial reporting to ensure future financial statement reliability.
• TTI-109 Phase 1 Data: Await the June 2026 topline data release for the TTI-109 healthy volunteer study to assess the viability of the next-generation inhibitor.
• Supplier Concentration: Note that Vendor A accounted for 41% of operating expenses and 72% of accounts payable in Q1 2026, indicating significant supply chain concentration risk.